London
20 °C
Manchester
Glasgow
18 °C
Dublin
Belfast
17 °C
Washington
26 °C
Denver
Atlanta
Dallas
Houston Texas
New Orleans
El Paso
17 °C
Phoenix
Los Angeles
2 °C
0 °C
15 °C
13 °C
23 °C
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate
Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below
NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and pre-clinical proof-of-concept study results.
Conference Call and Webcast Details
The dial-in numbers for Protagonist's investor update on Monday, June 30th at 4:30 pm ET are:
US-based Investors: 1-877-407-0752
International Investors: 1-201-389-0912
Conference Call ID: 13754335
The webcast link for the event can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1724439&tp_key=584cdd1e86
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA potentially in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, oral hepcidin program, and oral obesity program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
+1 833 500 0061 ext 1
[email protected]
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
(T.Wright--TAG)
